BRAIN Biotech AG: 3M FY 24/25 - Starting the year with double digit sales growth in the core BRAINBiocatalysts division BRAINBiocatalysts organic growth at 11 % in Q1 Quantitative guidance looking at strong growth and solid adjusted EBITDA margin for BRAINBiocatalysts in FY 2024/25 Strong cash position maintained at € 17.8 million while reducing [ … ]

Biological gold recycling: BRAIN Biotech AG collaborates with PX Group on the PX Urban Mining Initiative Development of BioXtractor V2 pilot by BRAIN and PX Group and production of first BioGold nuggets from a local waste stream Extension of cooperation between the two companies as part of the PX Urban Mining Initiative PX Urban Mining Initiativ [ … ]

Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects Group cash and cash equivalents improved to € 27.2 million Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics Management sees a strong start to the new financial year Updated mid-term tar [ … ]